<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04391894</url>
  </required_header>
  <id_info>
    <org_study_id>CECF843A2201</org_study_id>
    <nct_id>NCT04391894</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease</brief_title>
  <official_title>A Randomized, Double-masked, Multicenter Study to Evaluate the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of Part 1 of the study is to determine the safety and efficacy of topical ocular&#xD;
      ECF843 compared to topical ocular vehicle for the relief of the signs and symptoms associated&#xD;
      with moderate to severe dry eye disease (DED).&#xD;
&#xD;
      Part 2 of the study is exploratory only and intended to explore potential areas of&#xD;
      differentiation between ECF843 and topical ocular vehicle for the treatment of subjects with&#xD;
      dry eye disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in 2 parts: Part 1 - efficacy and safety of ECF843 vs vehicle,&#xD;
      followed by Part 2 - exploratory assessment of ECF843 vs vehicle.&#xD;
&#xD;
      Part 1 uses a double-masked design where subjects will be randomized to receive BID or TID&#xD;
      treatment with either ECF843 or vehicle for 56 days.&#xD;
&#xD;
      Part 2 will be initiated only if safety and efficacy of ECF843 during Part 1 is demonstrated.&#xD;
      Part 2 is double-masked design of ECF843 versus vehicle for 84 days after a 2-week vehicle&#xD;
      run-in phase.&#xD;
&#xD;
      Approximately 800 subjects will need to be screened in Part 1 to have approximately 680&#xD;
      subjects randomized into the 56-day treatment period.&#xD;
&#xD;
      For Part 2, it is estimated that up to 200 subjects will need to be screened to randomize up&#xD;
      to 160 subjects into the 2 treatment arms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 6, 2020</start_date>
  <completion_date type="Actual">May 25, 2021</completion_date>
  <primary_completion_date type="Actual">May 13, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-masked</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Change from baseline in Symptom Assessment in Dry Eye (SANDE) score</measure>
    <time_frame>56 Days (baseline to End of Part 1)</time_frame>
    <description>The primary aim of the study is to demonstrate improvement in moderate to severe DED with ECF843. This will be evaluated by measuring signs and symptoms as primary estimands. The analysis of the primary estimands will be based on Full Analysis Set (FAS) 1. The two primary estimands are the change from baseline in SANDE symptom score and the change from baseline in composite corneal fluorescein staining score in Part 1. The SANDE scale is 0-100 mm with most severe at 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Change from baseline in composite corneal fluorescein staining score</measure>
    <time_frame>56 Days (baseline to End of Part 1)</time_frame>
    <description>The primary aim of the study is to demonstrate improvement in moderate to severe DED with ECF843. This will be evaluated by measuring signs and symptoms as primary estimands. The analysis of the primary estimands will be based on Full Analysis Set (FAS) 1. The two primary estimands are the change from baseline in SANDE symptom score and the change from baseline in composite corneal fluorescein staining score in Part 1.&#xD;
For the corneal staining scale, each of the five regions will be graded based on a scale of 0 to 4, with higher scores suggestive of higher degrees of corneal staining. After entry of the scores per region, the total or composite (sum) score for each eye will be automatically calculated (maximum score = 20/eye). A (+1) will be added to the sum score for any eye with the presence of filaments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Change from baseline in inferior and central corneal fluorescein staining</measure>
    <time_frame>56 Days (baseline to End of Part 1)</time_frame>
    <description>To evaluate the improvement of ECF843 vs vehicle in corneal damage by quadrant.&#xD;
For the corneal staining scale, each of the five regions will be graded based on a scale of 0 to 4, with higher scores suggestive of higher degrees of corneal staining. After entry of the scores per region, the total or composite (sum) score for each eye will be automatically calculated (maximum score = 20/eye). A (+1) will be added to the sum score for any eye with the presence of filaments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Incidence and severity of ocular and non-ocular adverse events</measure>
    <time_frame>56 Days</time_frame>
    <description>To evaluate the safety of ECF843 vs Vehicle</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">719</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>ECF843 0.45 mg/mL TID or vehicle (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ECF843 0.45 mg/mL TID or vehicle (Part 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ECF843 0.15 mg/mL TID or vehicle (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ECF843 0.15 mg/mL TID or vehicle (Part 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ECF843 vehicle TID (Part 1)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ECF843 vehicle TID (Part 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ECF843 0.15 mg/mL BID or vehicle (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ECF843 0.15 mg/mL BID or vehicle (Part 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ECF843 vehicle BID (Part 1)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ECF843 vehicle BID (Part 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ECF843 -Part 2 (concentration/frequency TBD from Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ECF843 -Part 2 (concentration/frequency TBD from Part 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ECF843-Part 2 vehicle(concentration/frequency TBD from Part 1)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ECF843-Part 2 vehicle(concentration/frequency TBD from Part 1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ECF843</intervention_name>
    <description>Topical ocular eye drop</description>
    <arm_group_label>ECF843 -Part 2 (concentration/frequency TBD from Part 1)</arm_group_label>
    <arm_group_label>ECF843 0.15 mg/mL BID or vehicle (Part 1)</arm_group_label>
    <arm_group_label>ECF843 0.15 mg/mL TID or vehicle (Part 1)</arm_group_label>
    <arm_group_label>ECF843 0.45 mg/mL TID or vehicle (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ECF843 vehicle</intervention_name>
    <description>Topical ocular eye drop</description>
    <arm_group_label>ECF843 vehicle BID (Part 1)</arm_group_label>
    <arm_group_label>ECF843 vehicle TID (Part 1)</arm_group_label>
    <arm_group_label>ECF843-Part 2 vehicle(concentration/frequency TBD from Part 1)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent must be obtained before any assessment&#xD;
&#xD;
          -  Adult male or female subjects 18 years of age or older&#xD;
&#xD;
          -  At least 6 months history of dry eye disease in both eyes&#xD;
&#xD;
          -  Must use, or feel the need to use, artificial tears/gels/lubricants on a regular basis&#xD;
&#xD;
          -  Composite corneal fluorescein staining score ≥ 4 (modified National Eye Institute&#xD;
             (NEI) scale) in at least one eye&#xD;
&#xD;
          -  Schirmer score ≥ 1 and ≤ 10 mm after 5 minutes in at least one eye&#xD;
&#xD;
          -  Patients with Sjögren's Syndrome must have dry eye&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ocular infection in either eye within 30 days prior to Screening&#xD;
&#xD;
          -  Use of artificial tears, gels, lubricants within 4 hours of the Screening Visit&#xD;
&#xD;
          -  Use of contact lenses in either eye within 14 days of Screening&#xD;
&#xD;
          -  Uncontrolled ocular rosacea&#xD;
&#xD;
          -  Clinically significant conjunctivochalasis in either eye&#xD;
&#xD;
          -  Other Corneal conditions affecting the corneal structure&#xD;
&#xD;
          -  Severe ocular conditions such as herpes, graft versus host disease, Stephen's Johnson&#xD;
             Syndrome, sarcoidosis&#xD;
&#xD;
          -  Currently active, or history of ocular allergies during the time of year the patient&#xD;
             will be participating in the study&#xD;
&#xD;
          -  Patients with current punctal plugs or punctal cauterization or occlusion&#xD;
&#xD;
          -  Chronic medications (both over the counter and prescription) that have not been stable&#xD;
             for at least 30 days prior to Screening.&#xD;
&#xD;
          -  Use of Restasis®, Cequa®, or Xiidra® within 30 days prior to Screening&#xD;
&#xD;
          -  Use of ocular, nasal, inhaled, or systemic corticosteroids within 30 days of Screening&#xD;
&#xD;
          -  History of malignancy of any organs system&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Azusa</city>
        <state>California</state>
        <zip>91702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92843</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rancho Cordova</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mount Dora</city>
        <state>Florida</state>
        <zip>32757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pittsburg</city>
        <state>Kansas</state>
        <zip>66762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>South Orange</city>
        <state>New Jersey</state>
        <zip>07079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cranberry Township</city>
        <state>Pennsylvania</state>
        <zip>16066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wilkes-Barre Township</city>
        <state>Pennsylvania</state>
        <zip>18702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maryville</city>
        <state>Tennessee</state>
        <zip>37803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Smyrna</city>
        <state>Tennessee</state>
        <zip>37167</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lakeway</city>
        <state>Texas</state>
        <zip>78738</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry Eye</keyword>
  <keyword>Sjogrens</keyword>
  <keyword>dry eye syndrome (DES)</keyword>
  <keyword>Keratoconjunctivitis sicca (KCS)</keyword>
  <keyword>keratitis</keyword>
  <keyword>Xerophthalmia</keyword>
  <keyword>Sjögren's Syndrome</keyword>
  <keyword>Sjogren's Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

